Abstract: Methods of purifying AAV particles using a chromatin-DNA nuclease (e.g., MNase), and compositions that include AAV particles and a chromatin-DNA nuclease (e.g., MNase) are described. Compositions and kits that include a chromatin-DNA nuclease (e.g., MNase) for the purification of AAV particles are also provided.

Abstract: Formulations for highly purified viral particles (e.g., adeno-associated virus (AAV) particles) are provided herein. The formulations include purified AAV particles that are substantially free of impurities (e.g., product-related impurities and process-related impurities), and one or more of a buffering agent, a cryoprotectant, a non-ionic surfactant, and optionally a pharmaceutically acceptable salt. In certain aspects, the formulation maintains or enhances stability and/or reduces or prevents aggregation of the purified AAV particles.

Abstract: Apparatus and methods for detecting an a biomarker indicative of an inflammatory condition, including a capillary tube adapted for one or more biomarkers to adhere to an interior surface thereof, a light source for energizing quantum dots conjugated with the biomarkers within the capillary tube, and a detection system for detecting and quantifying fluorescent energy emitted by the quantum dots in one or more predetermined wavelength ranges, each wavelength range being correlated to one and only one of the biomarkers. A method of stabilizing the fluorescence intensity of quantum dots is also disclosed.